Get to know our clinical trials

Clinical trial on the efficacy and safety of povorcitinib in participants with non-segmental vitiligo.

THE OBJECTIVE IS TO COMPARE THE EFFICACY OF POVORCITINIB 30 MG QD WITH PLACEBO AT WEEK 52 IN ADULTS WITH NON-SEGMENTAL VITILIGO.

Imagen Dr. Pedro Redondo Bellón, departamento de Dermatologia
Dr. Pedro Redondo Curriculum
Codirector Dermatology Department
Madrid headquarters
Status
In recruitment
headquarters
Madrid

Technical Summary

  • PHASE III, RANDOMIZED, DOUBLE-MASKED, 52-WEEK, PLACEBO-COMPARATIVE, DOUBLE-BLINDED STUDY OF THE EFFICACY AND SAFETY OF POVORCITINIB IN PARTICIPANTS WITH NONSEGMENTAL VITILIGO
  • Code EudraCT: 2023-505782-86-00
  • Protocol number: INCB 54707-303
  • Promoter: IncyteCorporation
  • Molecule/Drug: Povorcitinib
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.